Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is an uncontrolled, open-label, non-randomized Phase I study to investigate safety,
biodistribution, radiation dosimetry and pharmacokinetics of a single dose of BAY88-8223 in
Japanese patients with castration-resistant prostate cancer and bone metastases.